Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Ho Yeong Lim,V V Breder,Philippe Merle,Ahmed Omar Kaseb,Daneng Li,Yin-Hsun Feng,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Beiying Ding,Andrew X. Zhu,Ann-Lii Cheng

Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

2020

Richard S. Finn
Shukui Qin
Masafumi Ikeda
Peter R. Galle
Michel Ducreux
Tae-You Kim
Masatoshi Kudo
Ho Yeong Lim
V V Breder
Philippe Merle
Ahmed Omar Kaseb
Daneng Li
Yin-Hsun Feng
Wendy Verret
Derek-Zhen Xu
Sairy Hernandez
Beiying Ding
Andrew X. Zhu
Ann-Lii Cheng

4596Background: In the Phase III IMbrave150 trial, statistically significant and clinically meaningful improvements in OS and PFS were seen with atezo + bev vs sor in pts with unresectable HCC who ...

Keywords:

Oncology
Bevacizumab
Atezolizumab
Internal medicine
Clinical trial
Sorafenib
in patient
Hepatocellular carcinoma
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations